Clinical Trial of Prednimustine, Leo‐1031 (NSC‐134087), in Patients with Non‐Hodgkin Lymphomata and Chronic Lymphocytic Leukaemia Previously Treated with Steroids and Alkylating Agents

Publisher Website
Google Scholar
Abstract
Prednimustine, a chlorambucil ester of prednisolone, was administered to 16 patients with non-Hodgkin lymphomata (NHL) and 14 patients with chronic lymphocytic leukemia (CLL), all previously treated with steroids [prednisone] and alkylating agents [vincristine, streptonigrin, cyclophosphamide, chlorambucil, bleomycin, adriamycin, demethylepipodophyllotoxin-ethylidinegluco-pyranoside]. Response was obtained in 8 patients with NHL and 11 patients with CLL. Two NHL patients had long-lasting complete remissions. Median duration of response for lymphomata was 12 wk, for CLL more than 15 wk. Delayed reversible and rather pronounced myelosuppression was the major side-effect observed in median 6 wk from the start of prednismustine, with a median duration of 4 wk.